Page 20 - Delaware Medical Journal - December 2016
P. 20
support of the ATA guidelines7 that states that cytologically indeterminate thyroid nodules determined to have a malignancy risk of 5 percent or less with a molecular test can be clinically observed.
CONCLUSIONS
Patients displayed a strong preference for molecular testing instead of diagnostic indeterminate thyroid nodules. All patients in this series, 25/25 (100 percent)
REFERENCES
1. Henry MR, DeMay RM, Berezowski K. Follicular Neoplasm/Suspicious for Follicular Neoplasm. In: Ali SZ, Cibas ES eds. The Bethesda System for Reporting Thyroid Cytopathology. Springer Publishers. New York, NY: 2010:51-58.
2. Nikiforov YE, Carty SE, Chiosea SI et al. Impact of the multi-gene ThyroSeq next- generation sequencing assay on cancer diagnosis in thyroid nodules with atypia of undetermined significance/follicular lesion of undetermined significance cytology. Thyroid. 2015;25;1217-1223.
3. Nikiforov YE, Carty SE, Chiosea SI et al. Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/ suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay. Cancer. 2014;120:3627- 3634.
4. Gharib, H. Changing trends in thyroid practice: understanding nodular thyroid disease. Endocr Pract. 2004;10:31-39.
5. Russ G, Royer B, Bigorgne C, Rouxel
A, Bienvenu-Perrard M, Leenhardt L. Prospective evaluation of thyroid imaging reporting and data system on 4550 nodules with and without elastography. Eur J Endocrinol. 2013;168:649-55.
6. Maia FF, Matos PS, Pavin EJ, Zantut- Wittmann DE. Thyroid imaging and reporting data system score combined
with indeterminate thyroid nodules elected molecular testing over repeat percent) patients with no mutation on surveillance rather than surgery or repeat
The risk of malignancy among mutation
established. There are a number of factors currently that may mute the power of
with Bethesda System for malignancy risk stratification in thyroid nodules with indeterminate results on cytology.
Clin Endocrinol (Oxf). 2015;82:439-444.
7. Haugen, BR, Alexander EK, Bible KC, et
al. 2015 American Thyroid Association Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26:1-133.
8. Witt RL. Outcome of thyroid gene expression classifier testing in clinical practice. Laryngoscope. 2016;126:524- 527.
9. Pagan M, Kloos RT, Lin C et al. The diagnostic application of RNA sequencing in patients with thyroid cancer: an analysis of 851 variants and 133 fusions in 524 genes. Bioinformatics. 2016;17:61-70.
CONTRIBUTING AUTHOR
■ ROBERT L. WITT, MD, FACS is a Professor of Otolaryngology-Head & Neck Surgery at Thomas Jefferson University in Philadelphia, Penn., an Affiliate Professor of Biological Sciences at
the University of Delaware in Newark, Del., and Director of the Head & Neck Multidisciplinary Clinic at Helen F. Graham Cancer Center, Christiana Care in Newark, Del.
13. Nikiforov YE, Seethala RR, Tallini G et al. Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma a paradigm shift to reduce overtreatment of indolent tumors.
JAMA Oncol. 2016;2:1023-1029.
14. Nikiforov YE, Ohori NP, Hodak SP, et
al. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab. 2011;96:3390-3397.
15. An JH, Song K, Kim SK, et al. RAS mutations in indeterminate thyroid nodules are predictive of the follicular variant of papillary thyroid carcinoma. Clinical Endocrinology. 2015;82:760-766
16. Medici M, Kwong N, Angell TE, et al. The variable phenotype and low-risk nature of RAS-positive thyroid nodules.
BMC Medicine. 2015;13:2-9.
17. Pelizzo MR, Dobrinja C, Casal Ide E, et al. The role of BRAF(V600E) mutation as poor prognostic factor for the outcome of patients with intrathyroid papillary thyroid carcinoma. Biomedicine & Pharmacotherapy.2014;68:413-417.
18. Nishino M. Molecular Cytopathology for Thyroid Nodules: A Review of Methodology and Test Performance.
Cancer Cytopathology. 2016;124:14-27.
10.
11.
12.
Alexander EK, Kennedy GC, Baloch ZW et al. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. NEJM 2012;1-11.
Yip L, Wharry L, Armstrong MJ, et al. A clinical algorithm for fine-needle aspiration molecular testing effectively guides the appropriate extent of initial thyroidectomy. Ann Surg 2014;260:163-168.
Armstrong MJ, Yang H, Yip L, et al. PAX8/ PPARg rearrangement in thyroid nodules predicts follicular-pattern carcinomas,
in particular the encapsulated follicular variant of papillary carcinoma. Thyroid. 2014;24:1369-1374.
372
Del Med J | December 2016 | Vol. 88 | No. 12
